Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Assets Average (2016 - 2025)

Rocket Pharmaceuticals' Assets Average history spans 10 years, with the latest figure at $349.2 million for Q4 2025.

  • For Q4 2025, Assets Average fell 24.19% year-over-year to $349.2 million; the TTM value through Dec 2025 reached $349.2 million, down 24.19%, while the annual FY2025 figure was $429.1 million, 21.56% down from the prior year.
  • Assets Average for Q4 2025 was $349.2 million at Rocket Pharmaceuticals, down from $394.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $583.7 million in Q1 2021 and bottomed at $349.2 million in Q4 2025.
  • The 5-year median for Assets Average is $486.4 million (2022), against an average of $486.5 million.
  • The largest annual shift saw Assets Average surged 56.71% in 2021 before it dropped 24.19% in 2025.
  • A 5-year view of Assets Average shows it stood at $513.6 million in 2021, then dropped by 5.66% to $484.5 million in 2022, then increased by 20.23% to $582.6 million in 2023, then dropped by 20.92% to $460.7 million in 2024, then fell by 24.19% to $349.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Assets Average are $349.2 million (Q4 2025), $394.5 million (Q3 2025), and $446.0 million (Q2 2025).